What is 21 CFR Part 11 and why does it matter?

For companies operating in regulated industries including pharmaceuticals, medical devices and biotechnology, maintaining the integrity of electronic records and signatures is not just good practice, it is a regulatory requirement. The U.S. Food and Drug Administration (FDA) established Title 21 of the Code of Federal Regulations (CFR) Part 11 to define the criteria under which electronic records and signatures are considered trustworthy, reliable and equivalent to paper records. This post explains the intent of 21 CFR Part 11, why it matters, and how it affects operations in regulated industries.

What is 21 CFR Part 11, and why is it important for pharma, med‑device and biotech companies?

21 CFR Part 11 is the FDA regulation that specifies how electronic records and signatures must be managed to be considered dependable and legally equivalent to paper documentation. It applies to all records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted under any FDA record-keeping requirements. Its purpose is to permit the use of electronic records in place of paper records provided that defined technical and procedural controls are in place.

For pharmaceutical, medical device and biotechnology companies, this regulation is critical. These sectors rely heavily on accurate and secure data throughout the entire product lifecycle, from research and development to clinical trials, manufacturing and distribution. Every batch record, quality‑control test and standard operating procedure (SOP) must be meticulously documented.

The importance of 21 CFR Part 11 lies in its role in safeguarding data integrity and security. By defining strict requirements for electronic systems, the regulation helps prevent data tampering, unauthorised access and data loss. These controls ensure that all electronic records submitted to the FDA are authentic and reliable, which is fundamental for demonstrating product safety and efficacy. Adhering to these standards strengthens regulatory confidence and supports global patient safety objectives. Globally, regulators such as the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) maintain comparable expectations. Frameworks like EU GMP Annex 11 and the MHRA GxP Data Integrity Guidance mirror many of the same principles as 21 CFR Part 11, reinforcing consistent expectations for data integrity across regions.

What industries are affected by 21 CFR Part 11?

While 21 CFR Part 11 is most closely associated with the pharmaceutical and biotechnology sectors, it applies to all FDA-regulated industries that maintain electronic records. Any organisation that manages electronic GxP data for manufacturing, testing, clinical, or quality processes must ensure its systems meet the requirements of Part 11.

This includes:

• Pharmaceutical manufacturers: From small molecule drugs to large molecule biologics, where all manufacturing and quality data must comply with FDA record-keeping requirements.
• Biotechnology companies: Including developers of gene therapies, vaccines, and biologics.
• Medical device manufacturers: Required to maintain compliant records across design, manufacture, packaging, labelling, and servicing.
• Clinical Research Organisations (CROs): Organisations conducting clinical trials generate vast amounts of electronic data that must be managed in a compliant manner.
• Contract Development and Manufacturing Organisations (CDMOs): CDMOs that provide development and manufacturing services for pharmaceutical companies must ensure compliance across all processes and data management.
• Food and beverage producers: Certain sectors of the food industry, especially those dealing with safety and traceability records, are also affected.
• Cosmetic companies: Companies making health-related claims about their products may also be subject to these requirements.

In summary, any life-sciences organisation that uses computerised systems to manage GxP data, whether under GMP, GLP, or GCP requirements, must comply with 21 CFR Part 11. These controls ensure that electronic systems used in regulated processes maintain the same level of trust and traceability as paper-based records.

What are the key components of the regulation?

21 CFR Part 11 establishes a framework of technical and procedural controls that protect the authenticity, integrity, and confidentiality of electronic records. The regulation is divided into two main areas: requirements for electronic records and for electronic signatures.

For electronic records, key components include:

• Validation: systems must be validated to ensure accuracy, reliability, and consistent performance.
• Audit trails: secure, computer‑generated, time‑stamped audit trails must independently record operator entries and all actions that create, modify, or delete electronic records.
• Access controls: systems must limit access to authorised individuals through unique user accounts, passwords and permissions.
• Record copies: the system must be able to generate accurate and complete copies of records in both human‑readable and electronic format.
• Data retention: records must be protected and retrievable throughout the required retention period.

For electronic signatures, key requirements include:

• Authentication: each electronic signature must be unique to a single authorised individual.
• Non‑repudiation: electronically signed records must include the printed name of the signer, the date and time of the signature, and the meaning associated with the signature (e.g. review, approval).
• Signature linking: signatures must be permanently linked to their respective electronic records to ensure they cannot be removed or altered.

How does compliance impact product quality and safety?

Compliance with 21 CFR Part 11 directly supports product quality and patient safety. By mandating robust controls over electronic data, the regulation ensures that the information used for critical manufacturing and quality decisions is reliable, traceable, and protected from unauthorised change.

In a manufacturing environment, electronic batch records document every step of the production process. A compliant system guarantees that all entries are attributable to a specific individual and time‑stamped. Any modifications are tracked in an audit trail, providing a complete history of the record. This transparency prevents unauthorised changes and ensures that any deviations from the approved process are documented and investigated.

What are the risks of non‑compliance?

Failing to comply with data-integrity expectations can result in serious consequences, starting with an FDA Form 483 observation and escalating to warning letters, product approval delays, or legal action. Such findings can damage an organisation’s reputation and interrupt operations.

By investing in robust digital systems and reliable electronic records, companies can not only meet global compliance standards but also protect product integrity, streamline inspections, and maintain their license to operate in highly regulated markets.

Ensure your compliance with Sepha

Achieving compliance with 21 CFR Part 11 depends on both sound procedures and reliable equipment. Sepha’s non-destructive leak-test and packaging systems are built to support data-integrity and compliance objectives through secure audit trails, role-based access controls, and validated software. Each system operates on a secure Windows IoT Enterprise LTSC platform with an integrated PC, removing the need for external computers. The machines connect directly to company networks so that batch reports and records are saved centrally and accessible only to authorised personnel. Sepha’s solutions align with international expectations, including EU GMP Annex 11 and the MHRA GxP Data Integrity Guidance.

To learn more about how Sepha’s technology can help you maintain 21 CFR Part 11 compliance and strengthen your data-integrity programme, contact our team today.